Hubbry Logo
Erythema induratumErythema induratumMain
Open search
Erythema induratum
Community hub
Erythema induratum
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Erythema induratum
Erythema induratum
Erythema induratum
View on Wikipedia
from Wikipedia
Erythema induratum
Erythema induratum
SpecialtyInfectious diseases Edit this on Wikidata

Erythema induratum is a panniculitis on the calves. It occurs mainly in women, but it is very rare now. Historically, when it has occurred, it has often been concomitant with cutaneous tuberculosis, and it was formerly thought to be always a reaction to the TB bacteria. It is now considered a panniculitis that is not associated with just a single defined pathogen.[1] The medical eponym Bazin disease was historically synonymous, but it applies only to the tuberculous form and is dated.

Pathophysiology

[edit]

Predisposing factors include abnormal amount of subcutaneous fat, thick ankles and abnormally poor arterial supply. Abnormal arterial supply causes low-grade ischemia of ankle region. The ankle skin becomes sensitive to temperature changes. When weather is cold, ankle is cold, blue and often tender. In hot weather, ankle becomes hot, edematous, swollen and painful. Chilblains may be present. On palpation, small superficial and painful nodules are felt. They break down to form small and multiple ulcers. Fresh crops of nodules appear in periphery of ulcer and ultimately break down. In nodular stage, pain is present; while it subsides in ulcerative stage.[2]

Diagnosis

[edit]

Mainly clinical.

Eponym

[edit]

The name Bazin disease honors Pierre-Antoine-Ernest Bazin.[3][4]

Additional images

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Erythema induratum

View on Grokipedia
from Grokipedia
Erythema induratum, also known as nodular or Bazin's disease, is a rare chronic characterized by recurrent crops of tender, erythematous nodules or plaques that primarily affect the lower legs, often in association with . It manifests as a reaction to antigens, classified as a tuberculid, though idiopathic cases and associations with other infections or conditions exist. First described by French dermatologist Pierre-Antoine-Ernest Bazin in 1861, the condition was historically linked exclusively to , but modern classifications distinguish between tuberculous (Bazin type) and non-tuberculous (Whitfield type) forms. It predominantly occurs in middle-aged women, with a strong female predominance (up to 11:1 ratio), and is more prevalent in regions with high tuberculosis rates, such as , , and , as well as and (where it comprises 35-40% of cutaneous TB cases as of 2025), though it remains uncommon in Western countries. The median age at onset is around 56 years, and risk factors may include , , and cold weather exposure. Pathophysiologically, erythema induratum involves a combination of type III (immune complex-mediated) and type IV (delayed-type ) reactions, leading to granulomatous , , and lobular on . In tuberculous cases, up to 89% of patients show positive skin tests, and lesions often arise without direct bacterial presence in the skin, supporting the mechanism; recent studies (as of 2025) confirm absence of non-tuberculous mycobacteria in lesions. Non-infectious etiologies include hepatitis C, autoimmune disorders, and certain drugs like , while other infections such as or have been implicated in isolated reports. Clinically, the lesions present as poorly defined, violaceous or erythematous nodules, typically 1-3 cm in diameter, located on the posterior calves; they are tender but non-pruritic and may ulcerate, heal with scarring, and recur over years. Systemic symptoms are uncommon, but about 50% of cases have an underlying focus, such as pulmonary or latent TB. Diagnosis relies on clinical features, showing and granulomas, and investigations like chest , , or interferon-gamma release assays to detect . The prognosis is generally favorable, with no reported fatalities, though the condition can be chronic and cause significant morbidity from and scarring; early treatment of underlying leads to resolution in most cases.

Background

Definition

Erythema induratum, also known as erythema induratum of Bazin, is a chronic, recurrent form of lobular that primarily involves of the subcutaneous fat layer. It typically manifests as tender, indurated nodules or plaques located predominantly on the posterior aspects of the lower legs. These lesions are erythematous and can evolve over time, often resolving spontaneously but with a tendency to recur in crops. Within the broader classification of panniculitides, erythema induratum falls under the spectrum of nodular , distinguished by its involvement of both subcutaneous fat and vascular structures, though may not always be prominent. Historically, it has been linked to reactions associated with infection, positioning it as a tuberculid in the context of cutaneous manifestations of . This association underscores its etiological ties to latent or active , though the condition can occur independently in some cases. The key morphological features of erythema induratum include firm, reddish-brown plaques or nodules that measure 1 to 3 cm in diameter and may coalesce. These lesions frequently undergo central ulceration, discharging a seropurulent material before healing, often leaving atrophic scars or hyperpigmented marks. The chronic nature of the disease leads to persistent or relapsing episodes, particularly in cooler seasons, affecting the aesthetic and functional aspects of the lower extremities.

History and Eponyms

Erythema induratum was first described in 1861 by the French dermatologist Pierre-Antoine-Ernest Bazin, who characterized it as a nodular eruption on the lower legs of young women with , associating it with scrofuloderma—a form of cutaneous . Bazin viewed the condition as a benign erythematous manifestation linked to underlying tuberculous infection, predating the discovery of the tubercle bacillus by in 1882. Over time, the understanding of erythema induratum evolved from a strictly tuberculosis-specific entity to a hypersensitivity reaction potentially triggered by Mycobacterium tuberculosis antigens, even in the absence of active disease. In 1901, A. Whitfield hypothesized the existence of two forms: a tuberculous type (Bazin type) and a non-tuberculous, idiopathic type (Whitfield type). In 1945, Hamilton Montgomery and colleagues introduced the term "nodular vasculitis" to describe similar lesions not directly associated with active tuberculosis, thereby broadening the diagnostic scope while acknowledging the tuberculous origins in many cases. This reclassification highlighted the condition's panniculitic nature and its relation to immune-mediated responses rather than direct infection. The "Bazin's disease" or "erythema induratum of Bazin" persists in modern dermatological literature to honor the original description, though it is often used interchangeably with nodular vasculitis in contexts where association is confirmed. This nomenclature underscores the historical tie to while reflecting contemporary views on its .

Epidemiology

Demographics

Erythema induratum predominantly affects middle-aged women, with a mean age at onset around 40–50 years (range from to elderly). The condition exhibits a marked female predominance, with female-to-male ratios ranging from 4:1 to 11:1 across studies, though both sexes can be affected. The disease shows higher incidence in regions with endemic , such as parts of and , where tuberculosis remains prevalent, although cases occur worldwide, including in low-burden areas like Western countries. There is no strong ethnic predisposition independent of tuberculosis exposure.

Risk Factors

The primary risk factor for erythema induratum is exposure to , which can lead to latent or active infection, triggering a reaction manifesting as the condition. Individuals with prior or current infection are particularly susceptible, as the disease represents a tuberculid form of cutaneous involvement. Other risk factors include , , and exposure to cold weather, which may contribute to development particularly in non-tuberculous cases. increases vulnerability, notably through co-infection, which can exacerbate latent TB and promote tuberculid reactions such as erythema induratum. Certain autoimmune conditions, including , have been associated in rare cases, potentially through overlapping vasculitic mechanisms. Streptococcal infections serve as infrequent triggers, possibly via immune-mediated pathways akin to other reactive dermatoses. Environmental risks encompass residence in regions with high tuberculosis prevalence, such as parts of (e.g., , ) and , where increased M. tuberculosis exposure heightens susceptibility. Poor socioeconomic conditions further facilitate TB transmission in these areas, indirectly elevating the risk for erythema induratum by promoting infection spread.

Pathophysiology

Etiology

Erythema induratum is primarily associated with a reaction to antigens derived from , manifesting even in individuals without active infection. This condition is classified as a tuberculid, representing a cutaneous to mycobacterial antigens that have disseminated hematogenously from a distant focus. Supporting evidence includes a high rate of positivity on the skin test, with one retrospective study of 65 patients reporting 89% positive results, indicating strong to tuberculin. Furthermore, affected individuals often demonstrate clinical improvement with multidrug antituberculous therapy, such as regimens containing isoniazid, rifampin, pyrazinamide, and ethambutol, which underscores the etiological role of M. tuberculosis antigens. Although the tuberculous association predominates, rare cases occur without identifiable M. tuberculosis involvement and may be idiopathic or linked to other triggers, including chronic hepatitis C infection or medications such as and .

Disease Mechanism

Erythema induratum develops through a complex immune-mediated process involving both type III (immune complex) and type IV (delayed-type) reactions, primarily triggered by persistent antigenic stimulation, such as from or its components. These reactions target the subcutaneous vasculature and , leading to lobular characterized by of the fat lobules. The type III component involves the deposition of antigen-antibody complexes in vessel walls, activating complement and attracting neutrophils, which contribute to initial endothelial damage and acute . Concurrently, the type IV reaction recruits T-lymphocytes and macrophages, fostering a granulomatous response that amplifies tissue injury. At the cellular level, the endothelial damage from these mechanisms disrupts vascular integrity, promoting fibrinoid and in medium-sized arteries and veins of the subcutaneous fat. infiltration predominates early, releasing enzymes and that exacerbate local tissue destruction and initiate fat cell (lipophagic ). As the process evolves, chronic inflammation involves multinucleated giant cells and epithelioid histiocytes forming granulomas around necrotic foci, further compromising blood flow through vascular occlusion. This ischemic environment sustains death and , distinguishing erythema induratum from other panniculitides. The disease progresses from discrete inflammatory nodules due to localized and fat lobule involvement to ulceration when ischemia becomes severe, allowing bacterial or further breakdown of the overlying skin. Vascular occlusion plays a central role in this advancement, as thrombi and intimal proliferation reduce , leading to hypoxic and eventual lesion breakdown. This sequential pathway underscores the interplay between acute neutrophilic responses and chronic granulomatous changes in driving the chronic, recurrent nature of the condition.

Clinical Features

Signs and Symptoms

Erythema induratum typically presents as recurrent, painful, erythematous to violaceous nodules or plaques, most commonly located on the posterior aspects of the calves and ankles in the lower third of the legs, often bilaterally. These subcutaneous lesions, measuring 1-2 cm in diameter, are tender to and may appear as deep-seated indurations initially. The condition is chronic and relapsing, with new lesions emerging over weeks to months while older ones resolve. The nodules evolve progressively, starting as firm, tender areas that become increasingly violaceous before potentially ulcerating with central and crusting. Ulceration occurs in a subset of cases, leading to drainage of serosanguinous or purulent material, followed by healing that results in atrophic, hyperpigmented, or depressed scars. This scarring contributes to the protracted course, which can span years or even decades without intervention. Systemic symptoms are uncommon, with the disease generally remaining localized to the skin without associated . Mild fever or may rarely accompany active lesions, but constitutional symptoms are not typical.

Histopathology

Erythema induratum is characterized histopathologically by a predominantly lobular , often with associated affecting small- to medium-sized vessels in the subcutaneous fat. The inflammatory process involves both septal and lobular components, with a mixed cellular infiltrate composed primarily of lymphocytes, histiocytes, and multinucleated giant cells, alongside neutrophils and plasma cells in varying proportions. This infiltrate surrounds and extends into the fat lobules, contributing to the nodular appearance observed clinically. A hallmark feature is the presence of caseation-like or within the fat lobules, which may be focal or more diffuse, particularly in lesions associated with tuberculosis . Vascular changes include endothelial swelling, fibrinoid necrosis of vessel walls, and neutrophilic infiltration, with some form of evident in approximately 90% of cases and necrotizing in about 46% of biopsies. Granulomatous is common, manifesting as poorly formed tuberculoid or palisading granulomas, often with lipophagic features where histiocytes engulf lipid debris. Special stains, such as Ziehl-Neelsen for acid-fast bacilli, are typically negative in biopsy specimens, which supports the interpretation of erythema induratum as a hypersensitivity reaction rather than direct mycobacterial infection of the skin. In cases with confirmed tuberculosis elsewhere, rare identification of organisms may occur, but this is exceptional. Additional findings can include septal fibrosis and extension of inflammation into the lower dermis, further delineating the subcuticular involvement.

Diagnosis

Clinical Evaluation

The clinical evaluation of suspected erythema induratum begins with a detailed taking to identify potential (TB)-related risk factors, as the condition is often associated with infection or . Clinicians should inquire about prior TB exposure, including contact with infected individuals or a personal of pulmonary TB or latent infection, which is reported in approximately 50% of cases. Additionally, assessment includes family of TB, recent travel to or residence in TB-endemic areas such as parts of Asia or Africa, and any prior episodes of similar skin lesions, which may recur over years in crops. These elements help contextualize the patient's risk profile and differentiate erythema induratum from other nodular vasculitides. Physical examination focuses on the lower extremities, particularly the calves, where lesions typically manifest. reveals tender, erythematous-to-violaceous subcutaneous nodules or plaques, usually 1-4 cm in diameter, predominantly on the posterior or lateral aspects of the legs; confirms induration and tenderness, with variable pain. Evaluation also assesses for ulceration, which may present with central breakdown and a rolled border, as well as evidence of healing with atrophic scarring or in chronic cases. A brief reference to associated symptoms, such as pain and occasional systemic features like fever, supports the clinical suspicion but is not diagnostic on its own. To guide the urgency of further investigation, clinicians evaluate lesion chronicity—often indicated by a prolonged history of recurrent episodes spanning months to decades—and multiplicity, such as the presence of bilateral crops or dissemination beyond the calves, which may signal active underlying TB requiring prompt intervention. This initial non-invasive assessment establishes the foundation for distinguishing erythema induratum from mimics like while avoiding premature invasive procedures.

Diagnostic Tests

Diagnosis of erythema induratum relies on a combination of laboratory tests, imaging studies, and histopathological examination to confirm the condition and exclude alternative causes such as other forms of or . is essential for histopathological confirmation, typically performed via incisional or deep punch biopsy of an early to evaluate subcutaneous fat involvement. The specimen is submitted for hematoxylin and eosin staining, as well as cultures for bacterial, fungal, and acid-fast organisms; (PCR) testing for Mycobacterium tuberculosis DNA using IS6110 primers may be employed if mycobacterial involvement is suspected, though the organism is often not identified even with advanced methods. To assess for tuberculosis sensitivity, a tuberculin skin test (Mantoux or purified protein derivative [PPD] test) is commonly used, starting with 1 tuberculin unit (TU)/0.1 mL, followed by 5 TU/0.1 mL after 2-3 weeks if initial results are negative; an exaggerated response is often observed in affected patients. Alternatively, interferon-gamma release assays (IGRAs) such as QuantiFERON-TB Gold or T-SPOT.TB provide a blood-based evaluation of latent TB infection with higher specificity, particularly in individuals with prior BCG vaccination; studies have shown that IGRAs are often positive in patients with erythema induratum, particularly those associated with tuberculosis. Additional tests include chest (posteroanterior and lateral views) or computed tomography to detect latent or active pulmonary TB, which is present in a subset of cases. Blood work, such as (ESR) and (CRP), helps gauge inflammation, though these are typically normal in erythema induratum. Serologic tests like (ANA) and (ANCA) may be performed to rule out autoimmune mimics such as or . If tuberculosis testing is negative, serologic evaluation for hepatitis C, , and other potential infectious or systemic causes is recommended to identify non-tuberculous etiologies.

Management

Treatment Approaches

The primary treatment for erythema induratum associated with involves antitubercular therapy (ATT) following standard guidelines for drug-susceptible , typically a 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months followed by isoniazid and rifampin for 4 months (or longer if extrapulmonary or other factors). This approach targets the underlying infection and leads to improvement or resolution of skin lesions in approximately 76% of cases, with response often observed within 6 weeks. However, in low TB burden settings, erythema induratum often represents idiopathic nodular , and ATT may not be required even with positive TB tests, per recent analyses. Symptomatic management focuses on alleviating , pain, and ulceration. Corticosteroids, either topical or systemic (e.g., ), are commonly used to control acute and reduce tenderness, particularly in conjunction with ATT. Analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) provide relief for pain associated with nodules or ulcers, while wound care measures, including dressings and leg elevation, support healing of ulcerated lesions. In cases not associated with tuberculosis (idiopathic or linked to other etiologies), treatment emphasizes anti-inflammatory and immunosuppressive agents. Oral (360-900 mg daily in divided doses) is often the first-line option, resulting in rapid pain reduction within days and resolution in 4-6 weeks in most responsive patients. For recalcitrant disease, dapsone (50-100 mg daily) has shown efficacy in resolving nodular lesions, particularly in non-tuberculous nodular . (7.5-15 mg weekly) may be employed as a steroid-sparing immunosuppressant in persistent cases unresponsive to initial therapies, leading to sustained remission. Ongoing monitoring for recurrence is essential, with follow-up evaluations every 3-6 months post-treatment.

Prognosis and Complications

The prognosis for erythema induratum is generally favorable with appropriate treatment, as lesions typically resolve within several months, leading to excellent long-term outcomes in most cases. No fatal cases have been reported to date, though the condition can cause significant morbidity due to its chronic and recurrent nature if inadequately managed. Complications arise primarily from untreated or persistent disease and include chronic scarring, particularly atrophic and hyperpigmented scars from ulcerated nodules, as well as secondary bacterial infections such as stemming from ulceration. In rare instances, erythema induratum may signal or precede progression to active involving sites like the lungs, pleura, or lymph nodes, necessitating vigilant screening. Relapse rates can be as high as 52% within 24 weeks after treatment with certain regimens, highlighting the importance of complete treatment courses. Key factors influencing recovery include early diagnosis, thorough eradication of underlying tuberculosis, and patient adherence to multidrug therapy, all of which significantly reduce relapse risk. Outcomes are poorer in immunocompromised individuals, where the disease may persist despite aggressive intervention and potentially lead to antimicrobial resistance.

References

  1. https://dermnetnz.org/topics/nodular-vasculitis
  2. https://emedicine.medscape.com/article/1083213-overview
  3. https://www.dermatologyadvisor.com/home/decision-support-in-medicine/dermatology/erythema-induratum-erythema-induratum-of-bazin-nodular-vasculitis/
  4. https://patient.info/doctor/dermatology/erythema-induratum
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC12257070/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC12580264/
  7. https://www.ncbi.nlm.nih.gov/books/NBK606121/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC6074297/
  9. https://www.ncbi.nlm.nih.gov/books/NBK482220/
  10. https://pubmed.ncbi.nlm.nih.gov/11511831/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4008050/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2923933/
  13. https://jamanetwork.com/journals/jamadermatology/fullarticle/522203
  14. https://pubmed.ncbi.nlm.nih.gov/16820827/
  15. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06454-4
  16. https://www.unboundmedicine.com/5minute/view/5-Minute-Clinical-Consult/816445/all/Erythema_Induratum_of_Bazin
  17. https://pubmed.ncbi.nlm.nih.gov/32975298/
  18. https://karger.com/drm/article/241/1/27/916216/Nodular-Vasculitis-Retrospective-Study-of-an
  19. https://www.unboundmedicine.com/5minute/view/5-Minute-Clinical-Consult/816445/0.5/Erythema_Induratum_of_Bazin
  20. https://pubmed.ncbi.nlm.nih.gov/35735288/
  21. https://pubmed.ncbi.nlm.nih.gov/16021168/
  22. https://pubmed.ncbi.nlm.nih.gov/19620036/
  23. https://www.sciencedirect.com/science/article/pii/S0022347662801991
  24. https://www.unboundmedicine.com/5minute/view/5-Minute-Clinical-Consult/816445/3.3/Erythema_Induratum_of_Bazin
  25. https://pubmed.ncbi.nlm.nih.gov/19233721/
  26. https://pubmed.ncbi.nlm.nih.gov/9261466/
  27. https://emedicine.medscape.com/article/1083213-clinical
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC8604635/
  29. https://www.uptodate.com/contents/erythema-induratum-nodular-vasculitis
  30. https://www.sciencedirect.com/science/article/pii/B9780702034855000188
  31. https://www.sciencedirect.com/science/article/pii/S0740257016301101
  32. https://www.jaad.org/article/S0190-9622(08)00920-1/abstract
  33. https://www.sciencedirect.com/science/article/pii/B9781416039662000485
  34. https://www.racgp.org.au/getattachment/11ba12e5-f3b5-4c86-a244-a2674d398b85/attachment.aspx
  35. https://jamanetwork.com/journals/jamadermatology/fullarticle/1105142
  36. https://www.cdc.gov/tb/hcp/treatment/tuberculosis-disease.html
  37. https://emedicine.medscape.com/article/1083213-treatment
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC6352374/
  39. https://pubmed.ncbi.nlm.nih.gov/38320211/
  40. https://www.edoj.org.eg/vol006/0602/011/01.htm
  41. https://www.jnma.com.np/jnma/index.php/jnma/article/view/2751
  42. https://www.unboundmedicine.com/5minute/view/5-Minute-Clinical-Consult/816445/3.2/Erythema_Induratum_of_Bazin
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC12202318/
Add your contribution
Related Hubs
User Avatar
No comments yet.